Newswire (Published: Wednesday, January 22, 2020, Received: Wednesday, January 22, 2020, 4:22:07 PM CST)

Word Count: 444

2020 JAN 22 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news originating from Melbourne, Australia, by NewsRx correspondents, research stated, “The last decade has seen a remarkable shift in the treatment landscape of advanced prostate cancer, none more so than in the management of metastatic castration-naive disease. This narrative review will examine existing and emerging evidence supporting systemic therapy use for metastatic castration-naive prostate cancer (mCNPC) and provide guidance on the selection of these agents with respect to optimising patient outcomes.”

Financial supporters for this research include National Health and Medical Research Council (NHMRC), NHMRC, Victorian Cancer Agency Clinical Research Fellowship, Astellas Investigator-initiated grant.

Our news journalists obtained a quote from the research from Peter MacCallum Cancer Center, “The addition of either docetaxel (chemohormonal approach) or an AR pathway inhibitor (abiraterone, enzalutamide or apalutamide) is a reasonable standard of care option for men commencing long-term ADT for mCNPC. While the issue of disease volume as a predictive biomarker for docetaxel benefit has previously been debated, recent data support consideration of upfront docetaxel in all patients, regardless of metastatic burden. Decisions regarding systemic treatment for men with mCNPC should be based on comprehensive consideration of disease, patient and logistical factors. Multiple novel therapeutics for mCNPC are currently under active investigation. The introduction of potent systemic therapy earlier in the mCNPC disease course has resulted in dramatic improvements in clinical outcomes for patients.”

According to the news editors, the research concluded: “As the management of mCNPC continues to evolve, the future remains promising, with the expectation of ongoing improvements to patient outcomes and quality of life.”

For more information on this research see: Navigating Systemic Therapy for Metastatic Castration-naive Prostate Cancer. World Journal of Urology, 2020;():. World Journal of Urology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; World Journal of Urology - http://www.springerlink.com/content/0724-4983/)

The news correspondents report that additional information may be obtained from A.A. Azad, Peter MacCallum Cancer Center, Dept. of Medical Oncology, Melbourne, Vic, Australia. Additional authors for this research include E.M. Kwan, I.A. Thangasamy, J. Teh, O. Alghazo, N.J. Sathianathen and N. Lawrentschuk.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s00345-019-03060-7. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Medical Research Council

Places

Australia and New Zealand
North America
Australia
United States
Americas
Oceania
New York
Melbourne
New York City

Subjects

Science and Technology
      Scientific Research
            Medical Research
                  Clinical Outcomes
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
                  Clinical Outcomes
      Medical Specialties and Practices
            Urology
      Treatments and Therapies
            Medicinal Drugs